한빛사논문
- 조회241
Parshant Kumar Sharma 1,2,3,#, Nam-Young Kim 1,2,3,7,#*, Enkhzaya Ganbold 1,2, Ryun-Sang Seong 1,2, Yu mi Kim 4, Jeong Su Park 5, Young Kee Shin 1,7, Ho Seong Han 4*, Eun-Seong Kim 1,2, Sang Tae Kim 1,4,6*
1RFIC Bio Centre, Kwangwoon University, 20 Kwangwoon-ro, Nowon-Gu, Seoul 01897, South Korea
2Department of Electronics Engineering, Kwangwoon University, 20 Kwangwoon-ro, Nowon-Gu, Seoul 01897, South Korea
3NDAC Centre, Kwangwoon University, 20 Kwangwoon-ro, Nowon-Gu, Seoul 01897, South Korea
4Bioscience & Biotechnology Research Institute, Healthcare Innovation Park, Seoul National University College of Medicine, Goomi-ro, Bundanggu Seongnam City, Geonggeedo 13605, South Korea
5Department of Laboratory Medicine, Seoul National University Bundang Hospital 82, Goomi-ro, Bundanggu Seongnam City, Geonggeedo 13620, South Korea
6Department of Surgery, Seoul National University Bundang Hospital 82, Goomi-ro, Bundanggu Seongnam City, Geonggeedo 13620, South Korea
7Laboratory of Molecular Pathology and Cancer Genomics, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, South Korea
#These authors contributed equally to this work.
*Corresponding authors: Nam-Young Kim, Ho Seong Han, Sang Tae Kim
Abstract
The COVID-19 epidemic and its continuous spread pose a serious threat to public health. Coronavirus strains known as SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) variants have undergone genomic changes. The severity of the symptoms, the efficiency of vaccinations, and the transmission capacity of the virus can be impacted by these alterations. Point-of-care diagnostic assays can identify particular genetic or protein sequences that are exclusive to each variety. Currently, ultrafast, responsive, and accurate antibody detection faces several challenges. Here, we outline the fabrication, implementation, and sensing performance benchmarking of an ultrafast (5 s) and inexpensive (0.15 USD) assay with label-free sensing of SARS-CoV-2 S (Spike) / N (Nucleocapsid) protein and other variants in real patient samples. A label-free DNA aptameric capacitive bio-sensing device was used to detect SARS-CoV-2 variants. Our novel, cutting-edge bio-sensing device contains a Wooden quoits conformation structural aptamer (WQCSA)-based inter-digitated capacitor electronic (WQCSA-IDCE) system. WQCSA-aptamer was used as a switch-turn on response to achieve ultrasensitivity in the variable area of the SARS-CoV-2. The molecular beacon (MB) method was also used to measure the fluorescently colored SARS-CoV-2 S/N protein. These sensors can be used with several types of label-free DNA aptamers to act as rapid, affordable, and label-free biosensors for a variety of critical acute respiratory virus syndrome disorders.
논문정보
- Research article
- 2024년 06월 (BRIC 등록일 2024-07-01)
- 국내 연구진
- 바이오·의료융합 > 의료기기
관련 보도자료
- Bio통신원
- 2024. 08. 07
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
